By Fineline Cube 
Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of prostate‑specific membrane antigen (PSMA)‑positive metastatic hormone‑sensitive prostate cancer (mHSPC). This approval marks a further advancement of Pluvicto’s clinical application in China, moving from metastatic castration‑resistant prostate cancer (mCRPC) into the earlier‑stage mHSPC setting.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Date | 26 Aug 2026 |
| Product | Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) + ARPI |
| Indication | PSMA‑positive metastatic hormone‑sensitive prostate cancer (mHSPC) |
| Significance | Advancement from mCRPC to earlier‑stage mHSPC in China |
| Supporting Data | Phase 3 PSMAddition study |
Drug Profile & Mechanism of Action
- Molecule: Pluvicto – a radioligand therapy (RLT) combining a PSMA‑targeting ligand with the beta‑emitting radioisotope lutetium‑177
- Mechanism: Binds PSMA‑expressing prostate cancer cells and delivers targeted radiation, inducing tumour cell death while sparing surrounding tissue
- Combination Rationale: Pairing RLT with an ARPI in the hormone‑sensitive setting attacks the tumour through complementary mechanisms earlier in the disease course
- Patient Selection: PSMA‑positive disease, enabling precision targeting of radioligand therapy
Clinical Evidence – PSMAddition (Phase 3)
| Endpoint | Outcome (Pluvicto + ARPI vs. Control) |
|---|---|
| Radiographic Progression‑Free Survival (rPFS) | Significantly improved |
| Relative Risk of Radiographic Progression or Death | 33% reduction (HR 0.67; 95% CI 0.55–0.82) |
| Subgroup Consistency | rPFS benefit favoured the combination across all subgroups, regardless of baseline disease burden or de novo vs. recurrent mHSPC |
The pivotal Phase 3 PSMAddition study demonstrated that combination therapy with lutetium [177Lu] vipivotide tetraxetan significantly improved radiographic progression‑free survival compared to the control group, with subgroup analyses consistent with the overall population — reinforcing the breadth of benefit across the mHSPC patient landscape.
Market Impact & Outlook
- Earlier‑Line Expansion: Moving Pluvicto from mCRPC into mHSPC substantially enlarges the addressable patient population in China, where prostate cancer incidence continues to rise and is often diagnosed at advanced stages.
- RLT Category Leadership: The approval consolidates Novartis’s position at the forefront of radioligand therapy and signals the maturation of China’s nuclear medicine infrastructure as a growth channel.
- Competitive Dynamics: With a 33% reduction in progression risk and cross‑subgroup consistency, the Pluvicto + ARPI combination is positioned as a differentiated first‑line option against incumbent ARPI monotherapy standards in PSMA‑positive mHSPC.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical uptake, reimbursement, and commercial expectations for Pluvicto in China. Actual results may differ due to risks including market adoption, radioligand supply infrastructure, and competitive dynamics.-Fineline Info & Tech